- Home
- AFRM vs BIIB Comparison
AFRM vs BIIB Comparison
Compare AFRM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AFRM
- BIIB
- Stock Information
- Founded
- AFRM 2012
- BIIB 1978
- Country
- AFRM United States
- BIIB United States
- Employees
- AFRM N/A
- BIIB N/A
- Industry
- AFRM Business Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- AFRM Consumer Discretionary
- BIIB Health Care
- Exchange
- AFRM Nasdaq
- BIIB Nasdaq
- Market Cap
- AFRM 21.3B
- BIIB 18.7B
- IPO Year
- AFRM 2021
- BIIB 1991
- Fundamental
- Price
- AFRM $78.72
- BIIB $138.60
- Analyst Decision
- AFRM Buy
- BIIB Buy
- Analyst Count
- AFRM 23
- BIIB 27
- Target Price
- AFRM $68.68
- BIIB $188.09
- AVG Volume (30 Days)
- AFRM 5.1M
- BIIB 1.5M
- Earning Date
- AFRM 08-28-2025
- BIIB 07-31-2025
- Dividend Yield
- AFRM N/A
- BIIB N/A
- EPS Growth
- AFRM N/A
- BIIB 31.67
- EPS
- AFRM N/A
- BIIB 10.45
- Revenue
- AFRM $3,007,180,000.00
- BIIB $9,997,000,000.00
- Revenue This Year
- AFRM $39.35
- BIIB N/A
- Revenue Next Year
- AFRM $22.24
- BIIB N/A
- P/E Ratio
- AFRM N/A
- BIIB $13.26
- Revenue Growth
- AFRM 42.55
- BIIB 3.36
- 52 Week Low
- AFRM $27.20
- BIIB $110.04
- 52 Week High
- AFRM $82.53
- BIIB $207.59
- Technical
- Relative Strength Index (RSI)
- AFRM 64.83
- BIIB 62.98
- Support Level
- AFRM $74.92
- BIIB $127.00
- Resistance Level
- AFRM $78.78
- BIIB $135.38
- Average True Range (ATR)
- AFRM 3.85
- BIIB 4.29
- MACD
- AFRM 0.48
- BIIB 0.82
- Stochastic Oscillator
- AFRM 94.32
- BIIB 98.39
About AFRM Affirm Holdings Inc.
Affirm Holdings Inc offers a platform for digital and mobile-first commerce. It comprises a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The firm generates its revenue from merchant networks, and through virtual card networks among others. Geographically, it generates a majority share of its revenue from the United States.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.